Answers are grounded in this paper and cite their sources.
Here, we describe the first identification of colistin-heteroresistant Enterobacter cloacae in the United States. Treatment of this isolate with colistin increased the frequency of the resistant subpopulation and induced cross-resistance to the host antimicrobial lysozyme. This is the first description of heteroresistance conferring cross-resistance to a host antimicrobial and suggests that clinical treatment with colistin may inadvertently select for bacteria that are resistant to components of the host innate immune system.
No takes yet. Share an insight, caveat, or question.
Napier et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: